you know with this bit of volitility the stock is now on many radars.so in the stort term it is annoyingbut long term goodsit back, not long to high teenscheers it's all good
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress